SCHEMBL7511641

SCHEMBL7511641

CCOC(=O)[C@](C)(Cc1ccccc1OCCN1CCCCC1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 7/20 0.56
MMP9 P14780 7/20 0.56
MMP13 P45452 7/20 0.56
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 2/20 0.43
DRD3 P35462 3/20 0.43
DRD2 P14416 2/20 0.43
ADAM17 P78536 2/20 0.42
GAA P10253 1/20 0.42
HRH1 P35367 2/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7943605 0.87 MMP1 (0.75) MMP1MMP9MMP13ADAM17
SCHEMBL6929947 0.86 MMP1 (0.75) MMP1MMP9MMP13KDM4EADAM17
SCHEMBL5157944 0.86 MMP1 (0.75) MMP1MMP9MMP13KDM4EADAM17
SCHEMBL6929395 0.84 MMP1 (0.62) MMP1MMP9MMP13KMT2AKDM4E
SCHEMBL7553179 0.83 MEN1 (0.45) MMP1MMP9MMP13MEN1KMT2A
SCHEMBL7623528 0.82 MMP1 (0.51) MMP1MMP9MMP13MEN1KMT2A
SCHEMBL7952119 0.82 MMP1 (0.55) MMP1MMP9MMP13L3MBTL1KDM4E
SCHEMBL7511465 0.80 MMP1 (0.50) MMP1MMP9MMP13MEN1KMT2A
SCHEMBL6933401 0.79 MMP1 (0.77) MMP1MMP9MMP13KDM4EADAM17
SCHEMBL7511164 0.79 MMP13 (0.61) MMP1MMP9MMP13ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors AMERICAN CYANAMID COMPANY (US) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors MMP12, ADAM33, MMP2 MMP1 7/4885MMP9 16/4885MMP13 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.